Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine is a racemic arylcyclohexylamine **dissociative anesthetic** and non-competitive N-methyl-D-aspartate receptor antagonist. In the Field Trip Health ketamine-assisted psychotherapy program, ketamine was administered alongside structured psychotherapy rather than as a new proprietary ketamine formulation; the retrospective registered study evaluated real-world changes in depression, anxiety, and post-traumatic-stress outcomes following guided ketamine sessions and psychotherapy visits. Ketamine is FDA-approved as an anesthetic, while its use in these psychiatric conditions is generally off-label for racemic ketamine. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/016812s043lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine (Parke-Davis).